Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S
Front Immunol. 2019; 9:3175.
PMID: 30713538
PMC: 6346592.
DOI: 10.3389/fimmu.2018.03175.
Malm M, Tamminen K, Vesikari T, Blazevic V
Front Microbiol. 2016; 7:1570.
PMID: 27752254
PMC: 5045929.
DOI: 10.3389/fmicb.2016.01570.
Kuriakose A, Chirmule N, Nair P
J Immunol Res. 2016; 2016:1298473.
PMID: 27437405
PMC: 4942633.
DOI: 10.1155/2016/1298473.
Li J, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M
AIDS. 2014; 28(18):2649-57.
PMID: 25254301
PMC: 4267919.
DOI: 10.1097/QAD.0000000000000478.
Ratanji K, Derrick J, Dearman R, Kimber I
J Immunotoxicol. 2013; 11(2):99-109.
PMID: 23919460
PMC: 4002659.
DOI: 10.3109/1547691X.2013.821564.
The peptide specificity of the endogenous T follicular helper cell repertoire generated after protein immunization.
Leddon S, Sant A
PLoS One. 2012; 7(10):e46952.
PMID: 23077537
PMC: 3471970.
DOI: 10.1371/journal.pone.0046952.
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.
Li J, Brumme C, Lederman M, Brumme Z, Wang H, Spritzler J
PLoS One. 2012; 7(3):e34134.
PMID: 22479542
PMC: 3316607.
DOI: 10.1371/journal.pone.0034134.
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Gray G, Allen M, Moodie Z, Churchyard G, Bekker L, Nchabeleng M
Lancet Infect Dis. 2011; 11(7):507-15.
PMID: 21570355
PMC: 3417349.
DOI: 10.1016/S1473-3099(11)70098-6.
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.
Li J, Brumme Z, Brumme C, Wang H, Spritzler J, Robertson M
J Infect Dis. 2011; 203(7):976-83.
PMID: 21402549
PMC: 3068025.
DOI: 10.1093/infdis/jiq143.
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
Schooley R, Spritzler J, Wang H, Lederman M, Havlir D, Kuritzkes D
J Infect Dis. 2010; 202(5):705-16.
PMID: 20662716
PMC: 2916952.
DOI: 10.1086/655468.
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.
Macatangay B, Zheng L, Rinaldo C, Landay A, Pollard R, Pahwa S
Clin Vaccine Immunol. 2010; 17(9):1452-9.
PMID: 20631337
PMC: 2944467.
DOI: 10.1128/CVI.00498-09.
Molecular determinants of T cell epitope recognition to the common Timothy grass allergen.
Oseroff C, Sidney J, Kotturi M, Kolla R, Alam R, Broide D
J Immunol. 2010; 185(2):943-55.
PMID: 20554959
PMC: 3310373.
DOI: 10.4049/jimmunol.1000405.
Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.
Olemukan R, Eller L, Ouma B, Etonu B, Erima S, Naluyima P
Clin Vaccine Immunol. 2010; 17(6):910-8.
PMID: 20200187
PMC: 2884426.
DOI: 10.1128/CVI.00492-09.
Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.
Huang X, Fan Z, Borowski L, Rinaldo C
Clin Vaccine Immunol. 2009; 16(10):1504-16.
PMID: 19692626
PMC: 2756841.
DOI: 10.1128/CVI.00104-09.
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission.
John-Stewart G, Mbori-Ngacha D, Lohman Payne B, Farquhar C, Richardson B, Emery S
J Infect Dis. 2009; 199(6):889-98.
PMID: 19434932
PMC: 2891190.
DOI: 10.1086/597120.
Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.
Wang L, Cheng C, Ko S, Kong W, Kanekiyo M, Einfeld D
J Virol. 2009; 83(14):7166-75.
PMID: 19420074
PMC: 2704769.
DOI: 10.1128/JVI.00374-09.
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
Boaz M, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J
Clin Vaccine Immunol. 2008; 16(2):147-55.
PMID: 19091991
PMC: 2643552.
DOI: 10.1128/CVI.00326-08.
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.
Kutscher S, Dembek C, Allgayer S, Heltai S, Stadlbauer B, Biswas P
AIDS Res Ther. 2008; 5:22.
PMID: 18837993
PMC: 2569082.
DOI: 10.1186/1742-6405-5-22.